Medicare Aranesp Reimbursement Drops “Equitable Adjustment” To Procrit
Executive Summary
Medicare will no longer consider Amgen's Aranesp to be "functionally equivalent" to Johnson & Johnson's Procrit when reimbursing hospitals for outpatient use of the biological product